I have some interesting cancer news for you today. Check them out!
News from the statisticians
Hospitalizations for brain cancer 2006
“People in the Northeastern United States are one-third more likely than those in the South or West to be hospitalized for treatment of brain cancer or to have brain cancer when they are hospitalized for another illness or complication.” This is according to the recent statistical brief from the Agency for Healthcare Research and Quality (AHQR). 73,500 hospitalizations were related to brain cancer, which is 24.6 hospitalizations in 100,000, incurring $655.5 million in hospital costs.
News from the geneticists
U-M researchers ID gene involved in pancreatic cancer
This gene is called Ataxia Telangiectasia Group D Complementing gene (ATDC) and its expression means is on average having 20 times more in pancreatic cancer cells than in cells from a normal pancreas. It also makes pancreatic cancer cells resistant to current therapies, according to researchers at the University of Michigan. They found that ATDC is overexpressed in 90% of cases of pancreatic cancer.
News from the researchers
Mobile phone use not associated with melanoma of the eye
German researchers report that mobile phones do not cause melanoma of the eye (uveal melanoma) as previously feared. The study looked at 459 people with this type of melanoma and 1,194 without and followed them up to about 10 years. The authors concluded: “we observed no overall increased risk of uveal melanoma among regular mobile phone users or users of radio sets in Germany, where digital mobile phone technology was introduced in the early 1990s.”
News from the screening experts
Perspective Round Table: Screening for Prostate Cancer
Experts from Europe and North America have recently met to discuss the latest research results on the efficacy of screening for prostate cancer. This topic will be discussed in detail in a resource post on our Battling Cancer section next week. Stay tuned.
FDA Approved First DNA Test for Two Types of Human Papillomavirus
The US FDA announced the approval pf the first DNA test for the Human Papillomavirus (HPV) last week. The test can detect the DNA sequences for HPV type 16 and HPV type 18 in cervical cells. These two are the HPV types that commonly cause cervical cancers. The test, called Cervista HPV 16/18 is recommended for women aged 30 and above or those with “borderline cytology” e.g. suspicious but not so clear indication on the paps smear. It can be a very useful tool for risk assessment of cervical cancer.
Photo credit: stock.xchng